AbCellera Biologics Inc.
ABCL
Kedudukan dalam Saham
#4229
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Harga Saham
$11.70
Modal Pasaran
$3.79B
Perubahan (1 hari)
-1.97%
Perubahan (1 tahun)
99.57%
Negara
CA
Perdagangan AbCellera Biologics Inc. (ABCL)
Kategori
Healthcare
Nisbah P/B bagi AbCellera Biologics Inc. (ABCL)
Nisbah P/B pada October 2026 TTM: 4.22
Menurut laporan kewangan dan harga saham terkini AbCellera Biologics Inc., nisbah P/B semasa (TTM) ialah 4.22. Pada akhir 2023, nisbah P/B syarikat ialah 1.43.
Sejarah nisbah P/B untuk AbCellera Biologics Inc. dari 2018 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 4.22 | 414.44% |
| 2024 | 0.82 | -43.01% |
| 2023 | 1.43 | -38.80% |
| 2022 | 2.34 | -39.10% |
| 2021 | 3.84 | -70.56% |
| 2020 | 13.06 | -98.53% |
| 2019 | 885.28 | 15.51% |
| 2018 | 766.43 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.251 | 48.18% |
US
|
|
| 13.2547 | 214.21% |
US
|
|
| 4.208 | -0.25% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 46.56% |
NL
|
